
ALLO Stock Forecast & Price Target
ALLO Analyst Ratings
Bulls say
Allogene Therapeutics Inc has demonstrated a strategic pivot by adopting standard FC lymphodepletion in its ALPHA3 trial, aimed at enhancing patient safety while simplifying the treatment protocol, which may lead to improved protocol adherence and real-world adoption. The company also reported high patient consent rates for minimal residual disease (MRD) screening, indicating strong engagement in the study, which bodes well for recruitment and the potential scalability of their T-cell therapies. Additionally, positive feedback from investigators regarding the regimen's simplification suggests that the approach may reduce complexity and infection risks, further supporting Allogene's vision of broader patient eligibility and potential market reach.
Bears say
Allogene Therapeutics Inc faces significant risks related to the approval of its clinical assets, as delays or failures in achieving regulatory approval could adversely affect the company's stock value. Additionally, the inherent uncertainties in clinical trials introduce the possibility that the company's products may not demonstrate sufficient efficacy or safety, which could further jeopardize their potential commercialization. Given these factors, combined with regulatory and commercial risks, the outlook for Allogene’s financial performance remains unfavorable.
This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ALLO Analyst Forecast & Price Prediction
Start investing in ALLO
Order type
Buy in
Order amount
Est. shares
0 shares